Is EPRXF or BTI a better dividend investment in 2026?

EPRXF currently yields 65.79% with a 5% 5-year dividend growth rate. BTI yields 5.38% with 5% growth. The better choice depends on your goal: EPRXF offers higher current income.

What is the dividend yield difference between EPRXF and BTI?

EPRXF has a forward dividend yield of 65.79% ($2.00/share annually). BTI yields 5.38% ($3.15/share annually). The yield gap is 60.41 percentage points.

Home › Compare › EPRXF vs BTI

EPRXF vs BTI: Dividend Comparison 2026

EPRXF yields 65.79% · BTI yields 5.38%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EPRXF wins by $824.2K in total portfolio value

INVESTMENT

TIME HORIZON10 years

EPRXF

● Live price

65.79%

Share price

$3.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$861.9K

Annual income

$216,014.89

Full EPRXF calculator →

BTI

● Live price

5.38%

Share price

$58.47

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.7K

Annual income

$2,786.64

Full BTI calculator →

Portfolio growth — EPRXF vs BTI

📍 EPRXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EPRXF	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EPRXF + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EPRXF pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPRXF

Annual income on $10K today (after 15% tax)

$5,592.11/yr

After 10yr DRIP, annual income (after tax)

$183,612.66/yr

BTI

Annual income on $10K today (after 15% tax)

$457.40/yr

After 10yr DRIP, annual income (after tax)

$2,368.64/yr

At 15% tax rate, EPRXF beats the other by $181,244.01/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPRXF + BTI for your $10,000?

EPRXF: 50%BTI: 50%

100% BTI50/50100% EPRXF

Portfolio after 10yr

$449.8K

Annual income

$109,400.77/yr

Blended yield

24.32%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

EPRXF

No analyst data

Altman Z

-3.2

Piotroski

2/9

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.6% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPRXF buys

BTI buys

No recent congressional trades found for EPRXF or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEPRXFBTI

Forward yield	65.79% ✓	5.38%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$861.9K ✓	$37.7K
Annual income after 10y	$216,014.89 ✓	$2,786.64
Total dividends collected	$726.7K ✓	$14.3K
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples

Year-by-year: EPRXF vs BTI ($10,000, DRIP)

Year	EPRXF Portfolio	EPRXF Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$17,279	$6,578.95	$11,299	$598.92	+$6.0K → EPRXF
2	$29,113	$10,624.05	$12,794	$703.91	+$16.3K → EPRXF
3	$47,879	$16,728.95	$14,518	$829.07	+$33.4K → EPRXF
4	$76,944	$25,713.03	$16,513	$978.64	+$60.4K → EPRXF
5	$120,949	$38,618.52	$18,827	$1,157.84	+$102.1K → EPRXF
6	$186,148	$56,733.31	$21,518	$1,373.12	+$164.6K → EPRXF
7	$280,783	$81,604.23	$24,657	$1,632.46	+$256.1K → EPRXF
8	$415,475	$115,037.79	$28,329	$1,945.74	+$387.1K → EPRXF
9	$603,645	$159,085.84	$32,637	$2,325.33	+$571.0K → EPRXF
10	$861,915	$216,014.89	$37,708	$2,786.64	+$824.2K → EPRXF

EPRXF vs BTI: Complete Analysis 2026

EPRXF — Stock

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Full EPRXF Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this EPRXF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPRXF vs SCHD EPRXF vs JEPI EPRXF vs O EPRXF vs KO EPRXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.